Exchange Surveillance
- ASM Stage ILong Term Additional Surveillance Measure (LTASM) - Stage I
Price band ± 20%
Price
Trading Data
range barsReturns
absolute and vs benchmark indexAbout the Company
Shilpa Medicare Ltd produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.The product range of the company includes Oncology AP`s-Anastrozole,Bicalutamide,Carboplatin ,Gemcitabine HCI, Irinotecan HCl Trihydrate,etc.General APIs-Ambroxol HCl,Ticlopidine HCl,Buflomedil HCl ,Nifedipine ,Lamivudine ,etc.PRODUCTS UNDER DEVELOPMENT (Oncology)- Bendamustine Cladribine, Decitabine Disodium Pamidronate, Epirubicin Exemustane, Fludarabine Phosphate Idarubicine,etc.NUTRITIONAL SUPPLEMENTS-Chromium picolinate Chromium polynicotinate.DRUG INTERMEDIATES-Trans-4-amino cyclohexanol,2-Amino-3,5-dibromobenzaldehyde,1,3,5-Trimethoxy Benzene ,etc..The company also engagged in the business of Power, Bulk Drugs and Intermediates.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- HQ
- Raichur, Karnataka
- Chairman
- Omprakash Inani
- CEO & MD
- Vishnukant Chaturbhuj Bhutada
- Registrar
- KFIN Technologies Pvt. Ltd.
- Exchange
- NSE
- ISIN
- INE790G01031
Institutional Demand
passive ownership through ETFsContext
where this company sitsFrequently Asked
▶What is the share price of Shilpa Medicare Ltd today?
Shilpa Medicare Ltd (SHILPAMED) is trading at ₹864.3. The price shown is the latest available from the exchange feed and updates through the trading session.
▶What is SHILPAMED’s P/E ratio versus the sector?
SHILPAMED trades at a P/E of 132.0. Its industry median is shown alongside it in Key Stats, so you can see at a glance whether the stock is priced above or below the businesses it competes with. A lower P/E is not automatically cheaper — it can also reflect slower expected growth.
▶What is SHILPAMED’s dividend yield?
SHILPAMED has a dividend yield of 0.06%, based on dividends declared over the last twelve months against the current price. The full dividend history is on the News & Filings tab.
▶What is SHILPAMED’s 52-week high and low?
SHILPAMED has traded between ₹259.5 and ₹1,095 over the past year. The Trading Data block shows where the current price sits inside that band.
▶What is the market capitalisation of Shilpa Medicare Ltd?
Shilpa Medicare Ltd has a market capitalisation of ₹20,649 crore.
▶What is SHILPAMED’s return on equity?
SHILPAMED reports a return on equity of 3.9%. ROE measures profit generated per rupee of shareholder capital, and is most meaningful compared against others in Drug Manufacturers - Specialty & Generic.
▶Who are SHILPAMED’s competitors?
The Peers block on this page lists other Drug Manufacturers - Specialty & Generic companies with their price, P/E and market capitalisation. The Valuation tab compares multiples against the industry median in more depth.
▶What is SHILPAMED’s promoter holding?
Promoters hold 40.13% of SHILPAMED. The Ownership tab shows the full shareholding pattern — promoter, FII, DII and public — and how each has moved across recent quarters.
▶Which indices include SHILPAMED?
Index membership is listed in the Context block on this page, along with the weight SHILPAMED carries in each. That weight is what determines how much passive money tracks the stock.
▶Is Shilpa Medicare Ltd a good buy?
We do not publish buy or sell calls. What this page gives you instead is the evidence: our Value & Investment Index for where the price sits against its own history, the Fundamental Strength Index for the quality of the business, an investment checklist of criteria applied to every stock, and pros and cons generated from SHILPAMED’s own numbers. The judgement is yours.
SHILPAMED at a glance
Shilpa Medicare Ltd operates in the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector. Shilpa Medicare Ltd (SHILPAMED) last traded at ₹864.3, giving it a market capitalisation of ₹20,649 crore. The 52-week range is ₹259.5 to ₹1,095, and the price is 72% of the way up that range. It trades at a price-to-earnings ratio of 132.0. Promoters hold 40.13% of the company in the latest shareholding filing.
| Market cap | ₹20,649 crore |
|---|---|
| P/E | 132.0 |
| ROE | 3.9% |
| ROCE | 4.8% |